Protagonist Therapeutics, Inc. (PTGX)
PTGX Stock Price Chart
Explore Protagonist Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze PTGX price movements and trends.
PTGX Company Profile
Discover essential business fundamentals and corporate details for Protagonist Therapeutics, Inc. (PTGX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Aug 2016
Employees
124.00
Website
https://www.protagonist-inc.comCEO
Dinesh V. Patel
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
PTGX Financial Timeline
Browse a chronological timeline of Protagonist Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 19 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.62, while revenue estimate is $4.90M.
Earnings released on 6 Aug 2025
EPS came in at -$0.55 falling short of the estimated -$0.53 by -3.77%, while revenue for the quarter reached $5.55M , missing expectations by -34.20%.
Earnings released on 6 May 2025
EPS came in at -$0.19 surpassing the estimated -$0.50 by +62.00%, while revenue for the quarter reached $28.32M , beating expectations by +332.01%.
Earnings released on 21 Feb 2025
EPS came in at $1.98 surpassing the estimated $0.06 by +3.20K%, while revenue for the quarter reached $170.64M , beating expectations by +110.63%.
Earnings released on 7 Nov 2024
EPS came in at -$0.54 surpassing the estimated -$0.59 by +8.47%, while revenue for the quarter reached $4.68M , missing expectations by -87.95%.
Earnings released on 6 Aug 2024
EPS came in at -$0.50 matching the estimated -$0.50, while revenue for the quarter reached $4.17M , missing expectations by -47.91%.
Earnings released on 7 May 2024
EPS came in at $3.26 surpassing the estimated $1.19 by +173.95%, while revenue for the quarter reached $254.95M , beating expectations by +112.46%.
Earnings released on 27 Feb 2024
EPS came in at $0.44 surpassing the estimated $0.03 by +1.43K%, while revenue for the quarter reached $60.00M , beating expectations by +50.00%.
Earnings released on 2 Nov 2023
EPS came in at -$0.58 surpassing the estimated -$0.68 by +14.71%.
Earnings released on 3 Aug 2023
EPS came in at -$0.68 falling short of the estimated -$0.65 by -4.62%.
Earnings released on 4 May 2023
EPS came in at -$0.67 surpassing the estimated -$0.69 by +2.90%.
Earnings released on 15 Mar 2023
EPS came in at -$0.69 falling short of the estimated -$0.67 by -2.99%.
Earnings released on 8 Nov 2022
EPS came in at -$0.64 surpassing the estimated -$0.94 by +31.91%.
Earnings released on 4 Aug 2022
EPS came in at -$0.84 surpassing the estimated -$0.99 by +15.15%, while revenue for the quarter reached $859.00K , beating expectations by +86.74%.
Earnings released on 4 May 2022
EPS came in at -$0.43 surpassing the estimated -$0.67 by +35.82%, while revenue for the quarter reached $25.72M , beating expectations by +21.43%.
Earnings released on 28 Feb 2022
EPS came in at -$0.77 surpassing the estimated -$0.79 by +2.53%, while revenue for the quarter reached $8.62M , beating expectations by +69.91%.
Earnings released on 3 Nov 2021
EPS came in at -$0.70 falling short of the estimated -$0.67 by -4.48%, while revenue for the quarter reached $10.29M , beating expectations by +406.70%.
Earnings released on 4 Aug 2021
EPS came in at -$0.69 falling short of the estimated -$0.62 by -11.29%, while revenue for the quarter reached $2.27M , missing expectations by -56.19%.
Earnings released on 4 May 2021
EPS came in at -$0.54 surpassing the estimated -$0.57 by +5.26%, while revenue for the quarter reached $6.19M , beating expectations by +98.37%.
Earnings released on 10 Mar 2021
EPS came in at -$0.48 falling short of the estimated -$0.47 by -2.13%, while revenue for the quarter reached $5.65M .
Earnings released on 4 Nov 2020
EPS came in at -$0.21 surpassing the estimated -$0.61 by +65.57%, while revenue for the quarter reached $13.11M , beating expectations by +38.91%.
PTGX Stock Performance
Access detailed PTGX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.